Adefovir
- Generic Name
- Adefovir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N5O4P
- CAS Number
- 106941-25-7
- Unique Ingredient Identifier
- 6GQP90I798
- Associated Conditions
- -
- Associated Therapies
- -
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
- Conditions
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00986778
TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2009-08-17
- Lead Sponsor
- Tongji University
- Target Recruit Count
- 216
- Registration Number
- NCT00960518
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Haerbin Medical University, Ha'er'bin, Heilongjiang, China
🇨🇳Shanghai 10th Hospital of Tongji University, Shanghai, Shanghai, China
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT00922207
- Locations
- 🇨🇳
National Taiwan Uni Hospital; Gastro-Enterology Dept., Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital; Gastroenterology Division, Taipei, Taiwan
🇨🇳Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan
Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Inje University
- Target Recruit Count
- 30
- Registration Number
- NCT00798460
- Locations
- 🇰🇷
Ilsanpaik hospital, Goyang, Gyunggi, Korea, Republic of
Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
- Conditions
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00513968
- Locations
- 🇰🇷
Kangnam St. Mary's Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
- Conditions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Pharmasset
- Registration Number
- NCT00496158
- Locations
- 🇺🇸
Advanced Clinical Research Institution, Anaheim, California, United States
🇺🇸Saint Louis University, St. Louis, Missouri, United States
🇺🇸Methodist Transplant Physicians, Dallas, Texas, United States
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
- Conditions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Pharmasset
- Registration Number
- NCT00496002
- Locations
- 🇺🇸
Asheville Gastroenterology, Asheville, North Carolina, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇦🇺Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
- Conditions
- Interventions
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 629
- Registration Number
- NCT00410202
- Locations
- 🇺🇸
University Of Connecticut Health Center, Farmington, Connecticut, United States
🇹🇷Local Institution, Trabzon, Turkey
Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00409019
Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection
- First Posted Date
- 2004-11-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT00096785
- Locations
- 🇹🇭
Local Institution, Bankok, Thailand
🇺🇸Local Insitution, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.